trending Market Intelligence /marketintelligence/en/news-insights/trending/lrxfzoow4bdf0c-onik7zq2 content esgSubNav
In This List

Aradigm to delist from Nasdaq

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Aradigm to delist from Nasdaq

Aradigm Corp.'s common stock will be suspended from Nasdaq trading on Sept. 14.

The delisting comes after Aradigm failed to regain compliance with the exchange's $35 million minimum market value of listed securities. Aradigm received the noncompliance notice in March, and had until Sept. 4 to regain compliance.

Aradigm may request a hearing to appeal the delisting, and stay the suspension. The company said it is evaluating available options to regain compliance.

Hayward, Calif.-based Aradigm develops drugs for the prevention and treatment of severe respiratory diseases.